Elizabeth M. Kudlacz
Pfizer (United States)(US)
Publications by Year
Research Areas
Rheumatoid Arthritis Research and Therapies, Asthma and respiratory diseases, Neuropeptides and Animal Physiology, Autoimmune and Inflammatory Disorders Research, Spondyloarthritis Studies and Treatments
Most-Cited Works
- → Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor(2003)668 cited
- → Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors(2017)505 cited
- → Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection(2010)332 cited
- → Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year(2012)160 cited
- → The Novel JAK-3 Inhibitor CP-690550 Is a Potent Immunosuppressive Agent in Various Murine Models(2003)154 cited
- → Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis(2008)141 cited
- → Matrix Metalloproteinases Inhibition Attenuates Tobacco Smoke-Induced Emphysema in Guinea Pigs(2003)116 cited
- → Immunosuppression by the JAK3 Inhibitor CP-690,550 Delays Rejection and Significantly Prolongs Kidney Allograft Survival in Nonhuman Primates(2005)107 cited
- → The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia(2008)95 cited
- → The specificity of JAK3 kinase inhibitors(2007)95 cited